Latest Competition News

Lake Resources has disclosed an inadvertent breach of ASX Listing Rule 7.1 related to the timing of share issuance under an agreement with Acuity Capital. The company is taking steps to strengthen governance and prevent future errors.

Alexium International Group Limited has announced a pro rata non-renounceable rights issue to raise approximately AUD 6.77 million, primarily to repay shareholder loans and finance the acquisition of Microtek Laboratories' microencapsulation business.

Titomic Limited has landed a $1.7 million Early Manufacturing Development contract with a leading defense prime, aiming to fast-track production of advanced defense components using its proprietary cold spray additive manufacturing technology.

Desert Metals Limited has completed the first tranche of its capital raising, issuing 64 million shares to raise $416,000, with a shareholder meeting planned to approve a second tranche worth $834,000.

Genetic Signatures announces the upcoming departure of CEO Allison Rossiter, initiating a leadership transition as the company intensifies its focus on US market expansion.

Nova Minerals Limited has voluntarily suspended trading of its shares on the ASX pending a capital raising announcement expected on 17 December 2025.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Symal Group has locked in a $300 million revolving debt facility with major Australian banks, enhancing its financial flexibility to support strategic growth and acquisitions.

Oliver’s Real Food reported a notable 6.5% rise in same-store sales for November 2025 alongside a 22% reduction in expenses, signaling improved operational efficiency. Despite a slight revenue dip year-to-date, the company’s profitability metrics show encouraging signs as it heads into the holiday season.

Ovanti’s US payments brand Flote has partnered with cloud-native platform Gr4vy to launch scalable, responsible buy now pay later solutions in the US market starting 2026.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.